Hologic price target lowered to $90 from $95 at Raymond James

Raymond James lowered the firm’s price target on Hologic (HOLX) to $90 from $95 and keeps an Outperform rating on the shares. Hologic’s print was essentially in line, but revenue guidance was cut as the breast health business required a reassessment both out of a bolus and ahead of a product update, the analyst tells investors in a research note. The firm says fiscal 2025 looks a “little more irregular” than was hoped as the breast health organization navigates a slower end market, and management must prove that these dynamics are a blip.